ArticlePloS one2025
Burden of and Trends in urticaria from 1990 to 2021 in China: A time-trend analysis and comparison with the United States and United Kingdom based on the GBD 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the world's largest developing country, China is facing a huge burden of urticaria. Studying the variations in urticaria management strategies between China and developed nations could offer valuable insights for policy development and enhance urticaria control efforts.
methodsWe used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to acquire a detailed comprehension of the rates and trends of urticaria incidence and prevalence, DALYs burden, and control strategies in China and compared them with those in the United States and the United Kingdom.
resultsIn global both sexes, from 1990 to 2021, the all ages incidence of urticaria, age-standardized percent prevalence, and all ages DALYs cases increased from 84.8 (106, 95% UI: 74.5-96.2) to 117.0 (106, 95% UI: 104.1-131.0), 0.89% (95% UI: 0.79%-1.00%) to 0.90% (95% UI: 0.80%-1.02%), and 2.9 (106, 95% UI: 1.9-4.1) to 4.0 (106, 95% UI: 2.6-5.7), respectively. Meanwhile, the age-standardized incidence rate increased from 1529.2 (95% UI: 1355.9-1720.36) in 1990 to 1533.71 (95% UI:1358.4-1726.1) in 2021. The incidence counts and prevalence peaked in individuals aged 5-9 years for both males and females, and it shows a gradually decreasing trend in subsequent age groups. The number of incidences has shown a gradually increasing trend and the incidence was higher in female than male. In China, from 1990 to 2021, the all ages incidence of urticaria, age-standardized percent prevalence, and all ages DALYs cases increased from 16.06 (106, 95% UI: 13.97-18.23) to 17.30 (106, 95% UI: 15.37-19.25), 0.81% (95% UI: 0.71%-0.92%) to 0.79% (95% UI: 0.69%-0.90%), and 551.3 (103, 95% UI: 362.6-792.7) to 591.8 (103, 95% UI: 391.4-830.1), respectively. In general, over the past 30 years, urticaria has shown a slow growth trend in China. In the same period, age-standardized incidence rate (ASIR) decreased from 1342.4 (95% UI: 1176.0-1520.5) in 1990 to 1337.6 (95% UI: 1172.3-1514.7) in 2021.
conclusionClinical data for special populations such as the elderly, children, and pregnant women need to be further expanded and strengthened in China. High quality randomized controlled trial research is still needed for keeping pace with advancements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.